Tarlatamab

This review examines 10 years of BiTE immunotherapy, focusing on pancreatic cancer. It discusses the development of BiTEs, their therapeutic features, manufacturing challenges, and strategies for improving their efficacy in solid tumors like pancreatic cancer, drawing lessons from their use in other cancers.

The 22nd Annual Winter Lung Cancer Conference will focus on advances in neoadjuvant/adjuvant immunotherapy for early-stage NSCLC. FDA approved obecabtagene autoleucel for relapsed/refractory B-ALL, and new therapies like lurbinectedin and tarlatamab are transforming SCLC treatment. Real-world data shows apalutamide improves survival over enzalutamide in prostate cancer. LBL-034, a GPRC5D-targeting bispecific antibody, received orphan drug designation for multiple myeloma.

Lung cancer treatment advances include minimally invasive surgery, targeted therapies, immunotherapies, and genetic testing at MSK. New treatments like KRAS inhibitors and TIL therapy show promise. Early detection through screening and innovative methods like E-nose and liquid biopsies aim to improve survival rates.

Recent SCLC treatments include FDA approval of tarlatamab-dlle, positive trial results, and new agents like lurbinectedin. Immunotherapies atezolizumab and durvalumab improve survival but lack predictive biomarkers. Surgical options are limited to early-stage cases. Novel agents are more tolerable, shifting treatment paradigms.

New research on small cell lung cancer (SCLC) highlights potential for personalized therapies targeting DLL3 and TTF-1 biomarkers, improving patient outcomes.

New research in 'Oncotarget' identifies DLL3 and TTF-1 as promising biomarkers for personalized SCLC treatment, potentially improving patient outcomes through precision medicine.

Study of 64 SCLC patients reveals DLL3 in 70% of tumors, potential for Tarlatamab; TTF-1-positive tumors show better survival, suggesting prognostic value. Digital pathology tools enhance analysis, supporting precision medicine in SCLC.

Tarlatamab, from the DeLLphi-301 study, showed durable responses (median PFS 4.3 months, median duration of response 9.7 months) and a favorable safety profile, leading to FDA accelerated approval in May 2024 for relapsed/refractory SCLC. Early toxicities, mainly cytokine release syndrome, were manageable and diminished over time, with no late-onset toxicities observed.

Himisha Beltran discusses DLL3 as a target for neuroendocrine prostate cancer treatment, highlighting its high expression in neuroendocrine and small cell prostate cancers. She reviews clinical trials of DLL3-targeted T-cell engagers like Tarlatamab and MK-6070, emphasizing the importance of patient selection and addressing tumor heterogeneity. Beltran also explores the need for better biomarkers and imaging techniques, and the potential for combination therapies to treat mixed tumor populations.